Want to see ADAG full AI Analyst Report?
ADAG Stock Chart & Stats
$3.97
-$0.15(-7.28%)
At close: 4:00 PM EST
$3.97
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.30 - $4.85
Previous CloseN/A
Volume1.51K
Average Volume (3M)296.38K
Market Cap
$170.11M
Enterprise Value$37.85
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$6.26M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Sep 02, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding66,072,590
10 Day Avg. Volume323,107
30 Day Avg. Volume296,378
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside126.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Antibody Discovery PlatformA durable proprietary discovery and engineering platform supports repeatable generation of therapeutic antibody candidates, enabling a steady pipeline, higher probability of partner interest, and sustainable tech-led differentiation versus single-asset peers. Platform ownership supports licensing and collaboration revenue over multiple years.
Partnership-driven Revenue ModelRelying on collaboration revenue (upfronts, R&D reimbursements, milestones, and future royalties) provides diversified, non-product funding that can extend runway and reduce binary product-risk. Long-term this model can finance R&D and de-risk programs via partner resources and validation.
Improving Liquidity And Manageable LeverageA multi-hundred-million dollar cash position (preliminary) combined with low debt-to-equity improves near-term funding flexibility and reduces immediate refinancing risk, giving management room to advance clinical programs and negotiate partnerships without urgent dilutive financings.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow reflects structural funding needs: the company does not self-fund R&D and must access external capital or partner payments. Over months this elevates dilution and execution risk if milestone timing or partner receipts slip.
Highly Volatile Revenue And Uneven Gross ProfitLarge year-to-year swings and episodes of negative gross profit undermine predictability of cash flow and margin sustainability. This volatility complicates planning, raises the chance of missed milestones, and limits confidence that recent improvements will persist absent structural revenue sources.
Clinical-stage Execution & Funding DependenceAs a clinical-stage biotech with no product sales, long development timelines, regulatory hurdles, and partner-dependent funding create structural execution risk. Success hinges on clinical outcomes and partner decisions, making sustainable profitability and cash generation uncertain over the medium term.
Adagene News
ADAG FAQ
What was Adagene, Inc.’s price range in the past 12 months?
Adagene, Inc. lowest stock price was $1.30 and its highest was $4.85 in the past 12 months.
What is Adagene, Inc.’s market cap?
Adagene, Inc.’s market cap is $170.11M.
When is Adagene, Inc.’s upcoming earnings report date?
Adagene, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 43 days.
How were Adagene, Inc.’s earnings last quarter?
Adagene, Inc. released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Adagene, Inc. overvalued?
According to Wall Street analysts Adagene, Inc.’s price is currently Undervalued.
Does Adagene, Inc. pay dividends?
Adagene, Inc. does not currently pay dividends.
What is Adagene, Inc.’s EPS estimate?
Adagene, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Adagene, Inc. have?
Adagene, Inc. has 66,072,590 shares outstanding.
What happened to Adagene, Inc.’s price movement after its last earnings report?
Adagene, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -13.449%.
Which hedge fund is a major shareholder of Adagene, Inc.?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (126.70% Upside)
$9.00 (126.70% Upside)
Blogger Sentiment
Bullish
ADAG Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Neutral
Last 7 Days ▼ 6.6%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene, Inc.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$9.00
▲(126.70% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.72% Other Institutional Investors
96.20% Public Companies and
Individual Investors